Philippe Clezardin
Philippe Clezardin
Professor in Bone Oncology
Verified email at
Cited by
Cited by
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
S Boissier, M Ferreras, O Peyruchaud, S Magnetto, FH Ebetino, ...
Cancer research 60 (11), 2949-2954, 2000
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats
P Fournier, S Boissier, S Filleur, J Guglielmi, F Cabon, M Colombel, ...
Cancer research 62 (22), 6538-6544, 2002
Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer
A Boucharaba, CM Serre, S Grès, JS Saulnier-Blache, JC Bordet, ...
The Journal of clinical investigation 114 (12), 1714-1725, 2004
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
S Boissier, S Magnetto, L Frappart, B Cuzin, FH Ebetino, PD Delmas, ...
Cancer research 57 (18), 3890-3894, 1997
SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth
S Filleur, A Courtin, S Ait-Si-Ali, J Guglielmi, C Merle, A Harel-Bellan, ...
Cancer research 63 (14), 3919-3922, 2003
Integrin αvβ3 expression confers on tumor cells a greater propensity to metastasize to bone
I Pecheur, O Peyruchaud, CM Serre, J Guglielmi, C Voland, F Bourre, ...
The FASEB Journal 16 (10), 1266-1268, 2002
Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity
P Clézardin, FH Ebetino, PGJ Fournier
Cancer research 65 (12), 4971-4974, 2005
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis
F Daubiné, C Le Gall, J Gasser, J Green, P Clézardin
Journal of the National Cancer Institute 99 (4), 322-330, 2007
The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases
A Boucharaba, CM Serre, J Guglielmi, JC Bordet, P Clézardin, ...
Proceedings of the National Academy of Sciences 103 (25), 9643-9648, 2006
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer
JT Buijs, NV Henriquez, PGM Van Overveld, G Van der Horst, I Que, ...
Cancer research 67 (18), 8742-8751, 2007
Tumor αvβ3 integrin is a therapeutic target for breast cancer bone metastases
Y Zhao, R Bachelier, I Treilleux, P Pujuguet, O Peyruchaud, R Baron, ...
Cancer research 67 (12), 5821-5830, 2007
Bisphosphonates in cancer therapy
V Stresing, F Daubine, I Benzaid, H Mönkkönen, P Clezardin
Cancer letters 257 (1), 16-35, 2007
A cathepsin K inhibitor reduces breast cancer–induced osteolysis and skeletal tumor burden
C Le Gall, A Bellahcene, E Bonnelye, JA Gasser, V Castronovo, J Green, ...
Cancer research 67 (20), 9894-9902, 2007
Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment …
O Peyruchaud, B Winding, I Pécheur, CM Serre, P Delmas, P Clézardin
Journal of Bone and Mineral Research 16 (11), 2027-2034, 2001
Expression of thrombospondin (TSP1) and its receptors (CD36 and CD51) in normal, hyperplastic, and neoplastic human breast
P Clezardin, L Frappart, M Clerget, C Pechoux, PD Delmas
Cancer research 53 (6), 1421-1430, 1993
Increased Dickkopf-1 expression in breast cancer bone metastases
N Voorzanger-Rousselot, D Goehrig, F Journe, V Doriath, JJ Body, ...
British journal of cancer 97 (7), 964-970, 2007
Effects of bone-targeted agents on cancer progression and mortality
R Coleman, M Gnant, G Morgan, P Clezardin
Journal of the National Cancer Institute 104 (14), 1059-1067, 2012
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
D Santini, G Schiavon, B Vincenzi, L Gaeta, F Pantano, A Russo, ...
PloS one 6 (4), e19234, 2011
Recent insights into the role of integrins in cancer metastasis
P Clezardin
Cellular and Molecular Life Sciences CMLS 54 (6), 541-548, 1998
Bone metastasis: pathogenesis and therapeutic implications
P Clezardin, A Teti
Clinical & experimental metastasis 24 (8), 599-608, 2007
The system can't perform the operation now. Try again later.
Articles 1–20